|
|
|
|
Craig C. Mello, PhD |
Nobel Laureate Craig C. Mello, PhD, will share his knowledge and insight about RNA interference and gene therapy as a participant in panel discussions at two upcoming biotech events in Boston.
Xconomy is hosting, “What’s Hot in Boston Biotech,” on May 16, at which life sciences executives, researchers and investigators will discuss advancements in the world of biotechnology. Dr. Mello, Howard Hughes Medical Institute Investigator, the Blais University Chair in Molecular Medicine and distinguished professor of RNA therapeutics and professor molecular medicine, will be joined by Barry Greene, president of Alnylam Pharmaceuticals, in a panel discussion titled, “RNAi: From Lab Experiment to FDA Review.” The first commercial RNAi drug developed by Alnylam, which is expected to receive regulatory approval in 2018, is based on Mello’s breakthrough discovery of RNA interference that earned him the 2006 Nobel Prize in Medicine, alongside co-recipient Andrew Z. Fire, PhD, of Stanford University.
Mello will also participate in a life sciences panel discussion on May 21 at the Boston Athenaeum titled, “Biotechnology and its Impact on the Future of Greater Boston.” He will serve as a panelist along with Adam Koppel, MD, managing director of Bain Capital Biosciences Fund, and David Meeker, MD, CEO of KSA Therapeutics, Inc. Carl Zimmer, science writer with the New York Times, will moderate the discussion. Panelists will trace the journey of consumer and clinical products from the spark of an idea to product-testing in the lab. UMMS is a sponsor of the event.
For more details, visit: What’s Hot in Boston Biotech; and Biotechnology and its Impact on the Future of Great Boston
Related stories on UMassMedNow:
Media reports: First RNAi drug, based on Craig Mello discovery, nearing market
Boston Globe: Mello’s RNAi discovery propelling new advancements against disease
Telegram reports on advancements in RNAi treatments
